A make-or-break result for Australia's fallen biotech giant. The post CSL reports on 18 August. Can the healthcare giant ...

Australian biotech giant CSL is negotiating with Vifor Pharma Group to acquire the Swiss company for A$10 billion ($7.1 billion), says the Australian Financial Review. The acquisition would become the ...

At the time of writing, brokers tip some element of upside from each of these ASX shares. Find out more here. The post Buy, hold, sell: Telstra, BHP, CSL shares appeared first on The Motley Fool ...

Shares down 3.3%, face worst day since mid-Feb FY25 NPAT forecast below Visible Alpha consensus Final dividend of $1.45/share vs last year's $1.29 Aug 13 (Reuters) - Shares of CSL Ltd (CSL.AX), opens ...

CSL Ltd said on Tuesday the fees it pays people to donate blood plasma, the core ingredient of its treatments, were stabilising after COVID-19 movement restrictions forced the Australian biomedical ...

May 27 (Reuters) - Australia's drug regulator said on Wednesday it ‌was notified by biopharmaceutical giant ‌CSL's unit Seqirus that it will be discontinuing all strengths of their Benpen injection ...

(Reuters) -Australian drugmaker CSL Ltd on Tuesday set the list price of its one-time gene therapy for hemophilia B at $3.5 million, making it the world's most expensive treatment, following its ...

SHANGHAI, April 30 (Reuters) - Australia's CSL Ltd (CSL.AX), opens new tab said it's evaluating whether its drugs used in surgery would be exempted from 125% tariffs China imposed on U.S.-made goods, ...